Akums Drugs Boosts EBITDA Amidst Strategic European Expansion

In its recent financial disclosure, Akums Drugs unveiled a 12% YoY rise in Adjusted EBITDA for Q3, alongside a strategic €200 million European contract. The improved EBITDA was bolstered by enhanced CDMO segment profitability and reduced API losses, reflecting ongoing product mix refinements.

Akums Drugs and Pharmaceuticals Ltd., based in New Delhi, reported a notable 12% year-on-year increase in its Adjusted EBITDA for the quarter ending December 31, 2024. The company attributed these results to improved profitability in its core CDMO segment.

Despite a decline in total income, dropping 6.1% on a YoY basis, the company's operating performance showed strength with significant reduction in API EBITDA losses. Additionally, Akums' entry into a €200 million contract to supply products to the European market marks a pivotal move towards global expansion.

Managing Directors, Sanjeev Jain and Sandeep Jain, emphasized Akums' role as a preferred manufacturing partner in the pharmaceutical sector. They highlighted the company's strategic initiatives, such as in-licensing novel products for future growth, further anchoring Akums' commitment to innovation and global market presence.

(With inputs from agencies.)